Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02779790
Other study ID # CIHR-LMRs 2016
Secondary ID
Status Active, not recruiting
Phase N/A
First received May 13, 2016
Last updated May 18, 2016
Start date April 2016
Est. completion date January 2018

Study information

Verified date May 2016
Source University of Toronto
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Observational

Clinical Trial Summary

Obesity is a major risk factor for cardiovascular disease and diabetes. Weight loss is an important therapeutic goal for overweight and obese patients to reduce their risk of developing cardiovascular disease and diabetes. Liquid meal replacements (LMRs) are simple tools that may aid in weight loss and may improve weight-related risk cardiometabolic risk factors. There is a need to synthesize the evidence on LMRs and cardiometabolic risk to inform clinical practice guidelines. The authors propose to conduct a series of systematic review and meta-analysis of randomized controlled trials to evaluate the effect of LMRs on 4 areas of cardiometabolic risk: markers of adipsoity, glycemic control, established lipid targets, and blood pressure.


Description:

Background: Liquid meal replacements (LMRs) provide a mixture of carbohydrate, fat and protein, along with added vitamins and minerals in liquid ready-to-drink form or powder formulas that require mixing. They are designed to mimic a low-calorie meal and serve as a quick and easy source of calories to consume. Behavioral strategy tools are important to assist obese individuals in losing weight and maintaining weight loss. There is evidence that LMRs contribute to weight loss and may reduce related cardiometabolic risk factors.

Need for proposed research: An earlier meta-analysis demonstrated that partial meal replacement plans produced significant weight loss and improved weight-related cardiometabolic risk factors. Several controlled trials have since investigated the effect of liquid meal replacements on body weight and weight-related risk factors for disease. There is a need to update of the evidence of the effect of LMRs on cardiometabolic risk to inform dietary guidelines and public health policy development.

Objective: To synthesize the evidence of randomized controlled trials of the effect of LMRs on body weight, blood pressure, glycemic control and established lipid targets.

Design: The systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Data sources: MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by manual searches.

Study selection: The investigators will include randomized controlled trials of >= 2-weeks duration that assess the effect of LMRs versus control diets on body weight, blood pressure, markers of glycemic control and lipid profile.

Data extraction: Two or more investigators will independently extract relevant data and assess risk of bias using the Cochrane Risk of Bias Tool. All disagreements will be resolved by consensus. Standard computations and imputations will be used to derive missing variance data.

Outcomes: Four sets of outcomes will be assessed: (1) Markers of adiposity (body weight, BMI, body fat, waist circumference), (2) glycemic control (HbA1c, fasting glucose, and fasting insulin), (3) Established therapeutic lipid targets (LDL-cholesterol, non-HDL-cholesterol, apolipoprotein B, HDL-cholesterol, triglycerides), and (4) blood pressure (systolic blood pressure and diastolic blood pressure).

Data synthesis: Pooled analyses of the mean difference will be performed using the generic inverse variance method. Random-effects models will be used even in the absence of statistically significant between-study heterogeneity because they yield more conservative summary effect estimates in the presence of residual heterogeneity. Fixed-effects models will be used only if there are less than 5 included trials. Crossover trials will be assessed via paired analyses. Heterogeneity will be assessed by the Cochran Q statistic and quantified by the I2 statistic. To explore sources of heterogeneity, the investigators will conduct sensitivity analyses, in which each study is systematically removed. If there are >= 10 trials, the study investigators will conduct apriori subgroup analyses by liquid meal replacement type (diabetes-specific formula, soy-based formula and fiber-containing formula), age, health status (presence/absence of type 2 diabetes), comparator, dose, baseline measurements, study design (parallel, crossover), follow-up (<= 3 months, > 3 months) and risk of bias. Meta-regression analyses will assess the significance of categorical and continuous subgroup analyses. When >= 10 trials are available, publication bias will be investigated by funnel plots and formal testing using Egger and Begg tests. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.

Evidence assessment: The strength of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Knowledge translation plan: The results will be disseminated through interactive presentations at local, national and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition and obesity. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.

Significance: The proposed research will synthesize the highest quality evidence from randomized trials and aid in knowledge translation of the effect of LMRs on body weight and related cardiometabolic disease risk. It will strengthen the evidence-base for guidelines, improve health outcomes, by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1
Est. completion date January 2018
Est. primary completion date January 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Trials in humans

- Liquid meal replacement intervention

- Presence of a comparator diet (control diet)

- Diet duration >=2 weeks

- Viable outcome data

Exclusion Criteria:

- Non-human trials

- Observational studies

- Lack of suitable comparator diet

- No viable outcome data

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
Liquid Meal Replacements
An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.

Locations

Country Name City State
Canada The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital Toronto Ontario

Sponsors (5)

Lead Sponsor Collaborator
John Sievenpiper Banting and Best Diabetes Centre, Canadian Diabetes Association, Canadian Institutes of Health Research (CIHR), The Physicians' Services Incorporated Foundation

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003 May;27(5):537-49. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Markers of adiposity - body weight Body weight Up to 20 years No
Primary Markers of adiposity - Body Mass Index Body Mass Index (BMI) Up to 20 years No
Primary Markers of adiposity - body fat Body fat Up to 20 years No
Primary Markers of adiposity - waist circumference Waist circumference Up to 20 years No
Primary Glycemic control - HbA1c HbA1c Up to 20 years No
Primary Glycemic control - fasting glucose fasting glucose Up to 20 years No
Primary Glycemic control - fasting insulin fasting insulin Up to 20 years No
Primary Established therapeutic lipid targets - LDL-cholesterol LDL-cholesterol (LDL-C) Up to 20 years No
Primary Established therapeutic lipid targets - apolipoprotein B Apolipoprotein B (apo B) Up to 20 years No
Primary Established therapeutic lipid targets - non-HDL-cholesterol non-HDL-cholesterol (non-HDL-C) Up to 20 years No
Primary Established therapeutic lipid targets - HDL-cholesterol HDL-cholesterol (HDL-C) Up to 20 years No
Primary Established therapeutic lipid targets - triglycerides Triglycerides Up to 20 years No
Primary Blood pressure - systolic blood pressure Systolic blood pressure Up to 20 years No
Primary Blood pressure - diastolic blood pressure Diastolic blood pressure Up to 20 years No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2